The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Interim analysis of a Phase II trial of epcoritamab plus lenalidomide in treatment-naive FL
Swetha Thiruvengadam, MD, City of Hope, Duarte, CA, shares findings from the interim analysis of a Phase II investigator-initiated trial (NCT06112847) evaluating epcoritamab in combination with lenalidomide in treatment-naive follicular lymphoma (FL). Dr Thiruvengadam highlights that the combination showed high efficacy and a good safety profile, with longer follow-up needed to assess the durability of responses. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
